ConSynance Therapeutics is a clinical-stage biopharmaceutical company targeting rare central nervous system diseases.  We aim to turn breakthrough science into transformative therapies for patients, with our focus on Prader-Willi Syndrome, hypothalamic injury-induced obesity, and narcolepsy with cataplexy.